CELLECTAR BIOSCIENCES INC

Inactive Instrument

Analyst Reco. Cellectar Biosciences Inc Nasdaq

Equities

US15117F2039

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 29	Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	CI
May. 14	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	Mar. 28	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	Mar. 28	MT
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating	Jan. 09	MT
Investors lower their expectations	Jan. 08
Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating	22-08-08	MT
Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating	22-02-02	MT
Cellectar Biosciences : Says Data From Trial Show 16.7% Complete Response Rate in Rare Blood Cancer Patients; Shares Down	21-06-04	MT
CELLECTAR BIOSCIENCES : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating	20-12-28	MT
Cellectar Biosciences, Inc. Reports Positive Top-Line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of Clr 131	19-02-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer